A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy

This study will look at how a mobile based app called 'Dose Check' used along with Xultophy® helps the treatment in participants with type 2 diabetes mellitus (T2DM). Participants will get Xultophy® as prescribed by study doctor or will continue already prescribed treatment with Xultophy®. Participants will also be prescribed to use Dose Check app by study doctor. Participants will be asked to install the Dose Check app in their mobile phone, which will be supported with the correct dose of Xultophy®. The study will last for about 6 to 8 months.

开始日期2024-11-07

申办/合作机构

Novo Nordisk A/S

NCT06408532

/ Not yet recruiting临床4期IIT

The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial

The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate glycemic control despite twice-daily subcutaneous injections of premixed insulin and metformin. Participants will be randomly assigned to either the premixed insulin dose optimization group (control group) or IDegLira once daily group, and the difference in change in glycated hemoglobin levels from baseline to 16 weeks of treatment will be assessed between the two groups.

开始日期2024-04-30

申办/合作机构

北京大学人民医院

JPRN-UMIN000052156

/ RecruitingN/AIIT

Comparison of insulin degludec/liraglutide versus insulin degludec in multiple daily injection therapy on subjects with type 2 diabetes; time to reach target glycemic levels - Conparison of IDegLira vs IDeg in multiple daily injection therapy

开始日期2023-09-05

申办/合作机构-

100 项与德谷胰岛素/利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与德谷胰岛素/利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与德谷胰岛素/利拉鲁肽相关的专利（医药）

登录后查看更多信息

145

项与德谷胰岛素/利拉鲁肽相关的文献（医药）

2025-09-11·CURRENT DIABETES REVIEWS

Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Article

作者: Liu, Delong ; Yang, Zhiyong ; Su, Ning ; Zhang, Lina ; Bai, Lexie

Introduction::

Clinical trials indicate that IDegLira is effective in treating type 2 diabetes mellitus (T2DM). This study aims to assess the efficacy and safety of IDegLira in type 2 diabetes mellitus (T2DM) comprehensively.

Methods::

To identify relevant randomized controlled trials, we searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov. Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated using the Mantel-Haenszel approach for dichotomous outcomes. Mean Difference (MD) and 95% CI calculated by the inverse variance approach were applied to continuous outcomes.

Results::

Twelve randomized controlled trials involving 7628 participants were included in this study. Compared with control groups, IDegLira has a significant hypoglycemic effect in reducing hemoglobin A1c (MD = −0.66; 95% CI [−0.85, −0.47]; p < 0.00001), fasting plasma glucose (MD = −0.90; 95% CI [−1.40, −0.41]; p = 0.0003), self-measured plasma glucose (MD = −0.82; 95% CI [−1.22, −0.42]; p < 0.0001) and achieving the hemoglobin A1c level of < 7.0%(RR = 1.66; 95% CI [1.44, 1.92]; p < 0.00001) or < 6.5% (RR = 2.13; 95% CI [1.76, 2.57]; p < 0.00001). IDegLira outperforms insulin in achieving the target of HbA1c < 7.0 or < 6.5% without hypoglycemia and weight gain. Besides, IDegLira did not increase the incidence of adverse events and serious adverse events.

Discussion::

In this section, IDegLira's benefits on simultaneously achieving glycemic control, weight loss, and reduced hypoglycemia risk were summarized. The statistical results were carefully interpreted in conjunction with clinical concerns regarding T2DM complications, adverse effects, and cost-effectiveness differences. An expanded discussion was conducted on integrating individualized HbA1c goals as a dual endpoint, without increasing body weight or the risk of hypoglycemia. Finally, the limitations of the present study are indicated.

Conclusions::

IDegLira exhibits a favorable glycemic control effect and acceptable adverse effects in Type 2 Diabetes Mellitus (T2DM). Superior performance in the target glycemic control, particularly suitable for T2DM patients who do not reach the target hemoglobin A1c and have comorbid CVD or obesity.

2025-09-01·DIABETOLOGIA

Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial

Article

作者: Gómez-Medina, Ana M ; Pertuz-Noriega, Carlos E ; Gómez-Quesada, Yaline ; Villamil-Castañeda, Lina P ; Muñoz-Velandia, Oscar M ; Chaim, Salma N ; Aschner, Pablo ; Yepes, Carlos A ; Henao-Carillo, Diana C

Abstract:

Aims/objective:

The aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting.

Methods:

The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8–10 mmol/l), the time below range (TBR <3.0 or <3.8 mmol/l), and other glycaemic management metrics measured by continuous glucose monitoring.

Results:

Sixty-four patients were included in the analysis (32 in each group). They had a baseline HbA1c of 103 ± 11.6 mmol/mol (11.6 ± 1.7%) and age of 58 ± 12.4 years (means ± SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008). The TIR 3.8–10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008). The findings were consistent regardless of baseline HbA1c.

Conclusions/interpretation:

IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.

Trial registration:

Clinicaltrials.gov NCT05767255

Funding:

This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).

Graphical Abstract:

2025-08-01·DIABETES OBESITY & METABOLISM

What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin + GLP ‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes

Review

作者: Frias, Juan Pablo

Abstract:

Aims:

The fixed‐ratio combinations (FRCs) of a basal insulin and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), offer a once‐daily injectable treatment option for adults with type 2 diabetes (T2D), combining complementary mechanisms of action to target both fasting and postprandial hyperglycaemia. While randomized controlled trials have demonstrated their efficacy and safety, real‐world evidence (RWE) provides important insights into their effectiveness, tolerability and use across routine clinical practice.

Materials and Methods:

This is a narrative review of selected real‐world studies assessing the FRCs IDegLira and iGlarLixi in adults with T2D. Studies assessing the use of FRCs to intensify and simplify therapy, as well as their use in special populations such as older adults were reviewed and are summarized.

Results:

Among individuals inadequately controlled on oral antihyperglycaemic drugs (OADs), basal insulin ± OADs, or GLP‐1 RAs, initiation of FRC therapy consistently improved glycaemic outcomes, supported modest weight loss or stability, and was associated with a low risk of hypoglycaemia. FRCs have also been evaluated as a strategy for simplifying complex insulin regimens. Transitions from basal–bolus or premixed insulin to FRCs maintained or improved glycaemic control while reducing total daily insulin dose and injection burden.Evidence in special populations and clinical contexts further supports the utility of FRCs. In older adults, FRC use was associated with reductions in HbA1c and hypoglycaemia risk, along with improvements in treatment satisfaction and functional measures. During Ramadan fasting, iGlarLixi demonstrated favourable glycaemic control, low hypoglycaemia incidence, modest weight loss and high adherence. Studies assessing glycaemic control using continuous glucose monitoring showed improvements in time in range, reductions in time above range and stable time below range, indicating enhanced glycaemic stability without increased risk of hypoglycaemia.Two real‐world head‐to‐head studies comparing IDegLira and iGlarLixi found both FRCs to be effective and well tolerated. IDegLira was associated with greater weight loss and lower insulin dose requirements, while iGlarLixi showed advantages in postprandial glucose control. Both agents demonstrated significant improvements in HbA1c and low rates of hypoglycaemia.

Conclusions:

Collectively, these real‐world studies confirm that FRCs are effective, safe and patient‐centred treatment options for adults with T2D. Their simplified dosing, metabolic benefits and favourable safety profiles support their use for both therapy intensification and de‐intensification across a broad spectrum of clinical scenarios. These findings reinforce results from randomized controlled trials, providing further confidence in the role of FRCs in contemporary diabetes care.

项与德谷胰岛素/利拉鲁肽相关的新闻（医药）

2026-02-27

·医药云端工作室

优于司美格鲁肽！礼来公布口服 GLP-1RA 详细研究数据

编辑：子非鱼 2月26日，礼来公司公布了其口服GLP-1受体激动剂orforglipron与目前主流的口服司美格鲁肽（商品名：诺和益®）的头对头研究（ACHIEVE-3）详细数据。这项为期52周、纳入全球近1700名2型糖尿病患者的临床试验，为GLP-1赛道带来了一个明确的结论：在控糖和减重这两大核心指标上，礼来的在研新药orforglipron展现出了更优的疗效。图源：礼来官微具体数据显示，在接受最高剂量（36mg）治疗52周后，orforglipron组患者的糖化血红蛋白（A1C）平均降低了2.2%，而口服司美格鲁肽最高剂量组（14mg）的降幅为1.4%。在备受关注的减重效果上，差异更为显著：orforglipron 36mg组患者平均体重下降了8.9公斤（降幅9.2%），而口服司美格鲁肽14mg组的平均减重为5.0公斤（降幅5.3%）。这意味着，在相对减重幅度上，orforglipron高出73.6%。此外，在实现血糖达标（A1C<7%）的患者比例、改善血脂和血压等心血管风险指标方面，orforglipron也均显示出优势。这项研究之所以备受关注，关键在于它直接比较了两种同为“口服”形式的GLP-1药物，为医生和患者提供了未来更清晰的选择依据。 ACHIEVE-3 研究结果：图源：礼来官微除了疗效数据，orforglipron还有一个潜在的便利性优势：它是一种小分子非肽类药物，服用时无需像口服司美格鲁肽那样严格限定在餐前半小时并只能少量饮水，这可能会提高患者的长期用药依从性。当然，任何药物都需要平衡疗效与安全性。研究中，orforglipron因不良反应导致的停药率略高于口服司美格鲁肽（高剂量组分别为9.7% vs 4.9%），最常见的不良反应均为恶心、腹泻等胃肠道事件，这与该类药物的已知特性一致。礼来已基于其庞大的临床项目数据，向包括中国在内的全球40多个监管机构提交了orforglipron的上市申请。美国FDA预计将在2026年第二季度对其肥胖适应症做出审批决定，糖尿病适应症的申请也计划在今年晚些时候提交。如果获批，orforglipron不仅将为2型糖尿病患者提供一个强有力的新选择，更可能凭借其口服便利性和优异的减重数据，在规模巨大的肥胖治疗市场中与司美格鲁肽和替尔泊肽等相关友商明星产品展开正面竞争，进一步重塑全球代谢疾病治疗格局。声明：本公众号内容旨在为医药行业人士提供行业动态，并不构成任何就医/用药/购药/投资建议，你看到此内容并不意味着你是本公众号的特定读者，请谨慎阅读。关注公众号，获取可靠、专业的资讯和分析内容

临床结果

2026-02-26

·雪球

双赢联姻：通化东宝携手惠升生物，解码糖尿病市场新格局与未来合作潜力

2026年2月26日，一则重磅合作公告在医药圈激起千层浪。国产胰岛素龙头企业通化东宝（600867.SH）与四环医药旗下专注糖尿病领域的创新平台惠升生物正式签署《商业化合作协议》。根据协议，通化东宝获得惠升生物旗下两款核心产品——德谷门冬双胰岛素注射液（商品名：惠优加）和德谷胰岛素注射液（商品名：惠优达）在中国大陆地区的独家商业化权益。这不仅是两款产品的简单授权，更是两家在糖尿病领域各有建树的公司，在行业变革关键节点上的一次战略握手。本文将深入剖析：1）此次合作将为刚刚走出业绩低谷、实现扭亏为盈的通化东宝带来怎样的增长动能？2）惠升生物丰富的产品管线中，还有哪些“宝藏”适合与东宝的未来战略协同？一、业绩贡献分析：东宝的“第二增长曲线”迎来强引擎对于通化东宝而言，2025年是标志性的一年。公司成功扭转此前受集采影响的业绩波动，预计实现归母净利润约12.42亿元，同比大幅扭亏为盈。其核心驱动力在于胰岛素类似物（三代胰岛素）的爆发式增长，销量同比增幅超100%，并在第三季度收入规模历史性地超越了传统优势业务人胰岛素（二代胰岛素），实现了产品结构的里程碑式升级。在此背景下，引入惠优加与惠优达，绝非锦上添花，而是为这列已经启动的快车再加装一台强力引擎。1.切入高速增长的细分蓝海，市场潜力巨大合作的核心产品惠优加（德谷门冬双胰岛素）意义非凡。它是全球首款可溶性双胰岛素制剂，也是首个获批上市的国产德谷门冬双胰岛素注射液生物类似药，成功突破了国际专利壁垒，领先国内其他厂家至少两年。其原研药诺和诺德的“诺和佳”（Ryzodeg）在中国市场表现极为亮眼。根据诺和诺德2025年年报，其德谷门冬双胰岛素与德谷胰岛素两款同通用名产品在大中国区收入合计已高达约43亿元人民币。米内网数据显示，德谷门冬双胰岛素注射液在中国三大终端六大市场的销售额从2023年的超13亿元增长至2024年的超15亿元，已成为胰岛素TOP10产品中的第五名。这意味着，东宝切入的是一个已被原研验证、且仍在高速增长的数十亿级蓝海市场。2.与现有管线完美协同，强化“一站式”解决方案能力通化东宝的商业化优势在于其覆盖全国、深入基层的成熟网络。公司人胰岛素市场份额高达45.5%，稳居国内第一；全品类胰岛素销量市场份额位列行业第二。惠优加（双胰岛素）和惠优达（长效基础胰岛素）的加入，将与东宝已有的门冬胰岛素（餐时胰岛素）、甘精胰岛素（长效基础胰岛素）等产品形成强大的矩阵协同。治疗路径全覆盖：从基础胰岛素、预混胰岛素到最新的双胰岛素，东宝能为医生和患者提供更完整、更前沿的胰岛素治疗方案选择。推动治疗升级：双胰岛素制剂因其“一针兼顾空腹与餐后血糖”、“注射前无需摇匀”的便利性，正成为传统预混胰岛素升级的重要方向。东宝可凭借其强大的学术推广能力，加速这一治疗理念的普及和产品替代。3.商业化能力保障快速放量，直接贡献营收利润惠升生物作为研发型公司，在商业化覆盖上仍需时间。而通化东宝超过万家的医疗机构覆盖和成熟的渠道体系，能确保两款产品快速完成市场准入和终端覆盖。参考原研药诺和益（德谷胰岛素利拉鲁肽复方制剂）在中国市场收入从2022年的0.45亿元飙升至2024年的14.26亿元的惊人增速，作为国产首仿且更具价格优势的惠优加与惠优达，在东宝的渠道赋能下，有望在未来2-3年内迅速成为销售额达数亿乃至十亿量级的重要品种，显著增厚公司业绩。二、未来合作展望：惠升管线中的“潜在盟友”此次合作可能只是序幕。惠升生物作为国内少数实现糖尿病及并发症领域全产品覆盖的生物制药企业，其管线中超过30款产品犹如一座富矿。除了已授权的胰岛素，以下领域的获批或临近获批产品，与通化东宝的战略布局高度契合，是未来深度合作的潜在方向：1.GLP-1受体激动剂：决战未来赛道的核心拼图GLP-1类药物是当前糖尿病和减重领域无可争议的王者。惠升生物在此领域布局深远：司美格鲁肽注射液：其降糖适应症预计于2027年获批上市。这正是通化东宝自身也在全力推进的领域（公司司美格鲁肽类似药已完成III期临床）。双方在该产品上存在竞争，但也存在联合市场教育、共享渠道资源甚至共同开发新剂型（如口服剂型）的合作可能。双/多靶点创新药：惠升自主研发的GLP-1R/GCGR双靶点激动剂P052注射液已获批IND，临床前数据显示其减重效果显著优于司美格鲁肽。这类前沿产品与东宝布局的GLP-1/GIP双靶点激动剂（THDBH120）形成了差异化且互补的下一代产品矩阵，合作开发或商业化前景广阔。2.SGLT-2抑制剂：口服降糖药的重要补充SGLT-2抑制剂是当前指南推荐的一线口服降糖药，兼具心肾保护获益。惠升生物已拥有完整的SGLT-2i产品线：1类创新药脯氨酸加格列净片（惠优静）：国产第二个获批的SGLT-2抑制剂1类新药。不过，其国内商业化权利已授权给华东医药。仿制药达格列净片、恩格列净片：均已获批上市。这些口服药能与东宝的胰岛素、GLP-1注射液形成“口服+注射”的联合治疗方案，为患者提供更全面的血糖管理工具包。虽然加格列净已授权，但其他SGLT-2i仿制药的合作空间依然存在。3.复方制剂与下一代胰岛素：持续巩固领先优势德谷胰岛素利拉鲁肽注射液：此产品正是诺和诺德另一款明星产品“诺和益”（Xultophy），2022-2024年中国区收入复合增长率高达463%。惠升生物该产品已在研。值得注意的是，通化东宝自身的德谷胰岛素利拉鲁肽注射液已于2025年3月启动III期临床试验。这预示着双方在该前沿复方制剂上可能形成“竞合”关系。未来，不排除在研发数据共享、市场划分或生产工艺上寻求合作，共同做大国产替代蛋糕的可能性。胰岛素周制剂（HSP002）：惠升在研的周制剂胰岛素代表了更优的患者依从性方向，与东宝在研的超速效胰岛素等创新剂型共同指向了糖尿病治疗的未来。4.糖尿病并发症药物：延伸患者管理价值链惠升已获批的硫辛酸、甲钴胺、羟苯磺酸钙、依帕司他等，用于治疗糖尿病神经病变、视网膜病变等并发症。这些产品能与降糖药形成协同，帮助东宝构建从“降糖”到“并发症防治”的更长远、更深入的患者全生命周期管理生态。结语：从产品合作到生态协同通化东宝与惠升生物的合作，始于两款重磅产品的商业化授权，但其深远意义远不止于此。对于东宝，这是在业绩反转、结构升级的关键期，精准卡位下一代胰岛素市场，强化龙头地位的果断之举。对于惠升，则是借助行业最强渠道之一，快速实现创新成果商业化的捷径。展望未来，两家公司的合作有望超越单一产品，向更广泛的管线协同、研发联动乃至市场共拓演进。在糖尿病这个患者基数庞大、治疗需求持续升级的黄金赛道，这种“研发尖兵”与“渠道王者”的强强联合，不仅将加速优质国产药物的可及性，更可能重塑市场竞争格局，为双方乃至中国糖尿病防治事业打开全新的增长空间。此次联手，或许正是一个新时代的开端。$上证指数(SH000001)$$深证成指(SZ399001)$$创业板指(SZ399006)$

2026-02-18

·医药笔记

2025年全球GLP-1市场规模780亿美元

▎Armstrong 2025年，全球范围内8款GLP-1的市场规模达到779亿美元，同比增长51%，其中减重GLP-1销售额合计265亿美元，相比2024年实现翻倍增长，市场规模占比达到三分之一。 GLP-1市场规模首次超过PD-1/PD-L1，后者2025年市场规模581亿美元。GLP-1有望成为历史上首个千亿美元靶点，且这一里程碑有望在2026年即可实现。中国市场上，降糖GLP-1市场规模有所下滑，诺和诺德GLP-1销售额72.5亿元人民币，市场份额80%左右。 2025年为中国减重GLP-1的市场元年，诺和诺德销售额9亿元人民币，基本全部来自司美格鲁肽，相比2024年增长314%。值得注意的是，诺和诺德Xultophy（德谷胰岛素/司美格鲁肽）全球销售额50亿元人民币，中国市场19.6亿元人民币，占比达到40%。总结中国在GLP-1迭代研发竞争中扮演越来越重要的角色，包括长效化、多靶点、小分子等几个重点方向，且从2024年开始迎来出海热潮。未来在这一个千亿美元级别的赛道，中国创新药也将抢占一定市场份额。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

100 项与德谷胰岛素/利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A10AE56	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	欧盟	Novo Nordisk A/S	2014-09-18
2型糖尿病	冰岛	Novo Nordisk A/S	2014-09-18
2型糖尿病	列支敦士登	Novo Nordisk A/S	2014-09-18
2型糖尿病	挪威	Novo Nordisk A/S	2014-09-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病	临床1期	德国	Novo Nordisk A/S	2009-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05324462 (SPIRIT, Pubmed) 人工标引	N/A	2型糖尿病	175	IDegLira	膚壓糧夢鏇衊範鹽衊鹹(廠壓糧簾鹽簾壓選壓鑰) = 夢憲鏇簾獵廠襯齋醖艱淵齋製獵衊鏇壓範鹽鬱 (襯衊壓觸鏇膚選構顧鹹, - 1.6 ~ - 1.0) 更多	积极	2024-05-08
NCT03737240 (CTgov)	临床3期	2型糖尿病	145	IDegLira (IDegLira)	齋鬱醖積鹹憲夢簾壓餘(網簾艱鬱獵餘夢窪遞顧) = 廠獵蓋襯築構構醖艱選鑰醖艱齋積積糧鏇憲繭 (鬱糧鬱繭築顧夢鏇願遞, 2.29) 更多	-	2023-09-08
				Insulin Degludec (U-100)+Insulin Aspart (Basal-Bolus Insulin)	齋鬱醖積鹹憲夢簾壓餘(網簾艱鬱獵餘夢窪遞顧) = 壓餘遞蓋醖鑰鹹選蓋願鑰醖艱齋積積糧鏇憲繭 (鬱糧鬱繭築顧夢鏇願遞, 1.79) 更多
EASD2022	N/A	2型糖尿病 HbA1c \| c-peptide	73	Human BBT	廠夢夢願夢壓範網蓋艱(廠範鹹憲蓋遞壓鹽鬱構) = 10 (18%) patients reported at least one episode and 6 (10%) patients had more than one episode of mild hypoglycemia 鏇鏇齋鹹觸築製觸鑰獵 (願淵鏇餘齋簾鹽襯簾蓋 )	积极	2022-09-20
				IDegLira
DUAL I China (Pubmed \| J Diabetes)	临床3期	2型糖尿病	-	IDegLira	願窪鑰憲遞艱襯蓋願積(願廠齋築顧醖範鹽襯觸): ETD = -6.5 (95% CI, -7.96 ~ -5.04) 更多	积极	2022-06-01
				Degludec
NCT03172494 (DUAL I China, EASD2020)	临床3期	2型糖尿病	720	IDegLira	選選積淵鏇膚艱憲蓋衊(齋齋鏇範衊齋壓築構蓋): ETD = -0.59 (95% CI, -0.73 ~ -0.46) 更多	积极	2020-09-23
				IDeg
NCT03175120 (DUAL II China, EASD2020)	临床3期	2型糖尿病	453	IDegLira	觸簾簾醖願憲膚餘齋膚(鹹齋糧醖廠構齋範簾淵): P-Value = <0.0001 更多	积极	2020-09-23
				Insulin degludec
NCT03172494 (DUAL I China \| DUAL™ I China, CTgov)	临床3期	2型糖尿病	720	Insulin degludec/liraglutide (Insulin Degludec/Liraglutide)	鏇構壓糧餘憲鏇醖遞蓋(鑰醖獵顧鏇醖繭製蓋觸) = 鹹遞選獵窪範餘膚壓鑰膚齋夢鹹糧膚窪積艱夢 (鹽淵夢簾憲膚鹹夢蓋淵, 0.88) 更多	-	2020-07-07
				Insulin Degludec (Insulin Degludec)	鏇構壓糧餘憲鏇醖遞蓋(鑰醖獵顧鏇醖繭製蓋觸) = 遞齋壓窪範齋築鬱糧鹹膚齋夢鹹糧膚窪積艱夢 (鹽淵夢簾憲膚鹹夢蓋淵, 0.99) 更多
NCT03175120 (DUAL™ II China \| DUAL II China, CTgov)	临床3期	2型糖尿病	453	Insulin degludec/liraglutide (Insulin Degludec/Liraglutide)	選糧觸膚糧構襯構衊夢(憲顧範夢遞鏇齋築範壓) = 獵鏇衊醖觸齋獵憲鏇餘繭願觸窪廠選齋齋窪鬱 (憲齋鬱窪顧鹹繭遞夢糧, 1.14) 更多	-	2020-03-19
				Insulin Degludec (Insulin Degludec)	選糧觸膚糧構襯構衊夢(憲顧範夢遞鏇齋築範壓) = 鹹繭積襯餘繭構壓積鑰繭願觸窪廠選齋齋窪鬱 (憲齋鬱窪顧鹹繭遞夢糧, 1.19) 更多
NCT02420262 \| NCT01952145 (Pubmed \| Diabet Med)	临床3期	2型糖尿病	-	Insulin degludec/liraglutide (IDegLira)	淵積憲鏇膚憲選遞醖構(築選窪憲鹽襯淵窪築夢) = 鑰艱鹽夢繭鹽網蓋窪艱醖簾醖鏇選鏇鹹繭鹹願 (遞齋衊積遞醖獵廠簾鑰 ) 更多	-	2020-02-01
NCT02911948 (Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	210	metformin+degludec/liraglutide	艱願繭顧齋選顧膚繭淵(餘淵齋築選窪壓積鑰窪): ETD = -13.98 (95% CI, -16.41 ~ -11.55), P-Value = <0.0001 更多	优效	2019-12-01
				metformin+degludec